Company: OPGN
Filing Date: 2025-10-31
Form Type: 10-Q
Source: 0001829126-25-008771
Chunk: 76

Company: OPGEN INC
Filing Date: 2025-10-31
Form: 10-Q
Item: Part I, Item 8
Chunk 76
---
 of its issued and outstanding shares of common stock. All share
amounts and per share prices in this quarterly report have been adjusted to reflect the reverse stock split.

Subsequent
to the Company’s assignment of its office lease in April 2024, the Company has operated virtually. The Company operates in
one business segment.

Financial
Overview 

Revenue

Prior
to the repositioning of our business, we generated revenues from sales of our products, including sales of our products through our distribution
partners, such as our Unyvero instruments and consumables. We also generated revenue from sales by Ares Genetics of its AI-powered prediction
models and solutions. Revenues generated from our laboratory services related to services that we and our subsidiaries provided to customers.
Lastly, our collaboration revenues consisted of revenue received from research and development collaborations that we entered into with
third parties, such as our collaboration agreement with the Foundation for Innovative New Diagnostics.

Following
the acquisition of a controlling interest in the Company by AEI Capital Ltd. and the formation of CapForce as OpGen’s wholly-owned
subsidiary, we generate revenues from CapForce’s listing sponsorship and consulting services, and we anticipate generating revenues
from CapForce’s other business ventures including cross-border securities trading, advanced computational model-enabled investment
banking advisory and asset management services, and FinTech-enabled capital table management solutions via CapForce’s next generation
global digital investment banking platform.

Cost
of Products, Cost of Services, and Operating Expenses

Prior
to the repositioning of our business, our cost of products consisted of product and inventory costs, including materials costs and overhead,
and other costs related to the recognition of revenue. Cost of services related to the material and labor costs associated with providing
our services. Research and development expenses consisted primarily of expenses incurred in connection with our clinical and pre-clinical
research activities. Selling, general and administrative expenses consisted of public company costs, salaries, and related costs for administrative,
sales, and business development personnel.

Following
the acquisition of a controlling interest in the Company by AEI Capital Ltd. and the formation of CapForce as OpGen’s wholly-owned
subsidiary, the Company’s cost of sales will primarily be subcontractor and advisor fees and technology infrastructure costs associated
with providing our services. Research and development expenses consist of fees to expand and innovate CapForce’s digital investment
banking platform, and selling, general, and administrative expenses continue to consist of public company costs, salaries, and related
costs